Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/80785
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLincoff, M.en
dc.contributor.authorTardif, J.en
dc.contributor.authorNeal, B.en
dc.contributor.authorNicholls, S.en
dc.contributor.authorRyden, L.en
dc.contributor.authorSchwartz, G.en
dc.contributor.authorMalmberg, K.en
dc.contributor.authorBuse, J.en
dc.contributor.authorHenry, R.en
dc.contributor.authorWedel, H.en
dc.contributor.authorWeichert, A.en
dc.contributor.authorCannata, R.en
dc.contributor.authorGrobbee, D.en
dc.date.issued2013en
dc.identifier.citationAmerican Heart Journal, 2013; 166(3):429-434en
dc.identifier.issn0002-8703en
dc.identifier.issn1097-6744en
dc.identifier.urihttp://hdl.handle.net/2440/80785-
dc.description.abstractBACKGROUND: Peroxisome proliferator-activated receptors (PPARs) regulate transcription of genes involved in glucose uptake, lipid metabolism, and inflammation. Aleglitazar is a potent dual PPAR agonist with insulin-sensitizing and glucose-lowering actions and favorable effects on lipid profiles and biomarkers of cardiovascular risk. The AleCardio trial examines whether the addition of aleglitazar to standard medical therapy reduces the risk of cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and recent acute coronary syndrome. STUDY DESIGN: AleCardio is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. A total of 7,228 patients were randomized to aleglitazar 150 μg or placebo daily in addition to standard medical therapy. The primary efficacy end point is time to the first event of cardiovascular death, myocardial infarction, or stroke. Principal safety end points are hospitalization due to heart failure and changes in renal function. Treatment will continue until 7,000 patients are followed up for at least 2.5 years and 950 primary end point events are adjudicated. CONCLUSIONS: AleCardio will establish whether the PPAR-α/γ agonist aleglitazar improves cardiovascular outcomes in patients with diabetes and high-risk coronary disease.en
dc.description.statementofresponsibilityA. Michael Lincoff, Jean-Claude Tardif, Bruce Neal, Stephen J. Nicholls, Lars Rydén, Gregory G. Schwartz, Klas Malmberg, John B. Buse, Robert R. Henry, Hans Wedel, Arlette Weichert, Ruth Cannata and Diederick E. Grobbeeen
dc.language.isoenen
dc.publisherMosby Incen
dc.rightsCopyright © 2013 Mosby, Inc. All rights reserved.en
dc.subjectHumans; Myocardial Infarction; Diabetes Mellitus, Type 2; Oxazoles; Thiophenes; Peroxisome Proliferator-Activated Receptors; Treatment Outcome; Hospitalization; Morbidity; Risk Factors; Double-Blind Method; Middle Aged; Female; Male; Stroke; Acute Coronary Syndromeen
dc.titleEvaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trialen
dc.title.alternativeEvaluation of the dual peroxisome proliferator-activated receptor alpha/gamma agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trialen
dc.typeJournal articleen
dc.identifier.rmid0020131758en
dc.identifier.doi10.1016/j.ahj.2013.05.013en
dc.identifier.pubid18063-
pubs.library.collectionMedicine publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidNicholls, S. [0000-0002-9668-4368]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.